☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - July 2022

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Solriamfetol (Sunosi®) has been accepted for restricted use to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). The restriction limits use to patients who have failed to respond to modafinil or have a contraindication or intolerance to modafinil.

Delafloxacin (Quofenix®) has been accepted for restricted use for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of this infection. The restrictions limits use to patients with suspected or confirmed polymicrobial infection following treatment failure or when standard antibacterial therapies are not suitable. It is also noted that delafloxacin should be used on the advice of local microbiologists or specialists in infectious disease.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - July 2022' by emailShare 'SMC Update - July 2022' on FacebookShare 'SMC Update - July 2022' on TwitterShare 'SMC Update - July 2022' on LinkedInShare 'SMC Update - July 2022' on reddit


No Comments to “SMC Update - July 2022”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.